A subsequent meta-analysis of RCT investigating the effects of three MAO-B inhibitors, selegiline, rasagiline, and safinamide, revealed their efficacy in reducing symptoms of depression, particularly in patients with early-stage Parkinson’s disease [157]. Here, MAOB is linked to major depressive disorder.